Trefoil Therapeutics banks $28M to create first drug for genetic eye disorder

Right now, the only way to prevent blindness in patients with a group of genetic eye disorders called corneal dystrophies is with cornea transplant surgery. But Trefoil Therapeutics is looking to change that: It’s raised $28 million to push its regenerative treatment toward the clinic.

Leave a Reply

Your email address will not be published. Required fields are marked *